# Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)

> **NCT07362238** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 122 (estimated)

## Conditions studied

- Immune Thrombocytopenia
- Treatment

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT07362238
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2028-03
- **Final completion:** 2028-03
- **Target enrollment:** 122 (ESTIMATED)
- **Last updated:** 2026-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07362238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07362238, "Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT07362238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*